阿尔茨海默病的脑脊液生物标志物。
Cerebrospinal fluid biomarkers of Alzheimer's disease.
机构信息
Department of Neurology, Hope Center for Neuological Disorder, Washington University, School of Medicine, St. Louis, MO 63110, USA.
出版信息
Biomark Med. 2010 Feb;4(1):51-63. doi: 10.2217/BMM.09.83.
Abstract
Alzheimer's disease will reach epidemic proportions within the next 20-30 years if left unchecked. Currently, there are no treatments that prevent or slow Alzheimer's disease but many are being developed. Parallel efforts to develop biomarkers to aid in disease diagnosis and prognosis, and assess disease risk are currently underway. Clinicopathological and biomarker studies have demonstrated that Alzheimer's disease pathology can be detected preclinically. Using biomarkers to identify affected individuals prior to the onset of clinical symptoms and associated synaptic/neuronal loss should enable novel clinical trial design and early mechanism-based therapeutic intervention. This article summarizes the most promising cerebrospinal fluid biomarkers, highlights novel applications and current challenges, and provides a prediction on how the field may evolve in 5-10 years.
摘要
如果不加以控制，阿尔茨海默病在未来 20-30 年内将达到流行程度。目前，尚无预防或减缓阿尔茨海默病的治疗方法，但正在开发许多方法。目前正在并行努力开发生物标志物，以帮助诊断和预后疾病，并评估疾病风险。临床病理和生物标志物研究表明，阿尔茨海默病的病理学可以在临床前阶段检测到。使用生物标志物在出现临床症状和相关的突触/神经元丧失之前识别受影响的个体，应该能够实现新的临床试验设计和早期基于机制的治疗干预。本文总结了最有前途的脑脊液生物标志物，强调了新的应用和当前的挑战，并对该领域在 5-10 年内可能如何发展进行了预测。
相似文献
1
Cerebrospinal fluid biomarkers of Alzheimer's disease.
Biomark Med. 2010 Feb;4(1):51-63. doi: 10.2217/BMM.09.83.
2
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
Biomark Med. 2012 Aug;6(4):455-76. doi: 10.2217/bmm.12.42.
3
A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.
4
Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease.
Recent Pat CNS Drug Discov. 2010 Jun;5(2):172-8. doi: 10.2174/157488910791213194.
5
A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease.
Braz J Psychiatry. 2019 Nov-Dec;41(6):467-468. doi: 10.1590/1516-4446-2019-0629.
6
The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?
Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. doi: 10.2174/1574889811308010006.
7
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
Drugs Today (Barc). 2007 Jun;43(6):423-31. doi: 10.1358/dot.2007.43.6.1067341.
8
Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
J Alzheimers Dis. 2021;81(1):263-272. doi: 10.3233/JAD-201426.
9
Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Neurosci Lett. 2020 Jul 13;731:135078. doi: 10.1016/j.neulet.2020.135078. Epub 2020 May 23.
10
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
引用本文的文献
1
Using cerebrospinal fluid biomarkers to diagnose Alzheimer's disease: an Australian perspective.
Front Psychiatry. 2024 Dec 5;15:1488494. doi: 10.3389/fpsyt.2024.1488494. eCollection 2024.
2
Inhibiting mtDNA transcript translation alters Alzheimer's disease-associated biology.
Alzheimers Dement. 2024 Dec;20(12):8429-8443. doi: 10.1002/alz.14275. Epub 2024 Oct 23.
3
Possible Prophylactic Effects of Sulforaphane on LPS-Induced Recognition Memory Impairment Mediated by Regulating Oxidative Stress and Neuroinflammatory Proteins in the Prefrontal Cortex Region of the Brain.
Biomedicines. 2024 May 16;12(5):1107. doi: 10.3390/biomedicines12051107.
4
Precise prediction of cerebrospinal fluid amyloid beta protein for early Alzheimer's disease detection using multimodal data.
MedComm (2020). 2024 Apr 19;5(5):e532. doi: 10.1002/mco2.532. eCollection 2024 May.
5
Biomarkers: Role and Scope in Neurological Disorders.
Neurochem Res. 2023 Jul;48(7):2029-2058. doi: 10.1007/s11064-023-03873-4. Epub 2023 Feb 16.
6
Divalent 2-(4-Hydroxyphenyl)benzothiazole Bifunctional Chelators for Cu Positron Emission Tomography Imaging in Alzheimer's Disease.
Inorg Chem. 2022 Dec 19;61(50):20326-20336. doi: 10.1021/acs.inorgchem.2c02740. Epub 2022 Dec 4.
7
2-(4-Hydroxyphenyl)benzothiazole dicarboxylate ester TACN chelators for Cu PET imaging in Alzheimer's disease.
Dalton Trans. 2022 Jan 17;51(3):1216-1224. doi: 10.1039/d1dt02767k.
8
Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside.
Mol Neurobiol. 2022 Jan;59(1):657-680. doi: 10.1007/s12035-021-02617-1. Epub 2021 Nov 9.
9
Amentoflavone: A Bifunctional Metal Chelator that Controls the Formation of Neurotoxic Soluble Aβ Oligomers.
ACS Chem Neurosci. 2020 Sep 2;11(17):2741-2752. doi: 10.1021/acschemneuro.0c00376. Epub 2020 Aug 21.
10
Deciphering the factors that influence participation in studies requiring serial lumbar punctures.
Alzheimers Dement (Amst). 2020 Feb 6;12(1):e12003. doi: 10.1002/dad2.12003. eCollection 2020.
本文引用的文献
1
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease.
Proteomics Clin Appl. 2007 Nov;1(11):1373-84. doi: 10.1002/prca.200600999. Epub 2007 Oct 16.
2
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.
EMBO Mol Med. 2009 Nov;1(8-9):371-80. doi: 10.1002/emmm.200900048.
3
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
Arch Neurol. 2009 Dec;66(12):1557-62. doi: 10.1001/archneurol.2009.279.
4
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.
Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269.
5
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.
Nature. 2009 Oct 15;461(7266):916-22. doi: 10.1038/nature08538.
6
Relationships between biomarkers in aging and dementia.
Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.
7
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.
8
Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
Exp Gerontol. 2009 Sep;44(9):579-85. doi: 10.1016/j.exger.2009.06.003. Epub 2009 Jun 16.
9
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Lancet Neurol. 2009 Jul;8(7):619-27. doi: 10.1016/S1474-4422(09)70139-5. Epub 2009 Jun 10.
10
Safety of lumbar puncture procedures in patients with Alzheimer's disease.
Curr Alzheimer Res. 2009 Jun;6(3):290-2. doi: 10.2174/156720509788486509.
Zotero 插件